Tetsuya Kawakita1, Laura I Parikh2, Patrick S Ramsey3, Chun-Chih Huang4, Alexander Zeymo4, Miguel Fernandez5, Samuel Smith6, Sara N Iqbal2. 1. Department of Obstetrics and Gynecology, MedStar Washington Hospital Center, Washington, DC. Electronic address: tetsuya.x.kawakita@gunet.georgetown.edu. 2. Department of Obstetrics and Gynecology, MedStar Washington Hospital Center, Washington, DC. 3. Department of Obstetrics and Gynecology, University of Texas Health Science Center at San Antonio, San Antonio, TX. 4. Department of Biostatistics and Epidemiology, MedStar Health Research Institute, Hyattsville, MD. 5. Department of Obstetrics and Gynecology, Virginia Hospital Center, Arlington, VA. 6. Department of Obstetrics and Gynecology, MedStar Franklin Square Medical Center, Baltimore, MD.
Abstract
OBJECTIVE: We sought to determine predictors of adverse neonatal outcomes in women with intrahepatic cholestasis of pregnancy (ICP). STUDY DESIGN: This study was a multicenter retrospective cohort study of all women diagnosed with ICP across 5 hospital facilities from January 2009 through December 2014. Obstetric and neonatal complications were evaluated according to total bile acid (TBA) level. Multivariable logistic regression models were developed to evaluate predictors of composite neonatal outcome (neonatal intensive care unit admission, hypoglycemia, hyperbilirubinemia, respiratory distress syndrome, transient tachypnea of the newborn, mechanical ventilation use, oxygen by nasal cannula, pneumonia, and stillbirth). Predictors including TBA level, hepatic transaminase level, gestational age at diagnosis, underlying liver disease, and use of ursodeoxycholic acid were evaluated. RESULTS: Of 233 women with ICP, 152 women had TBA levels 10-39.9 μmol/L, 55 had TBA 40-99.9 μmol/L, and 26 had TBA ≥100 μmol/L. There was no difference in maternal age, ethnicity, or prepregnancy body mass index according to TBA level. Increasing TBA level was associated with higher hepatic transaminase and total bilirubin level (P < .05). TBA levels ≥100 μmol/L were associated with increased risk of stillbirth (P < .01). Increasing TBA level was also associated with earlier gestational age at diagnosis (P < .01) and ursodeoxycholic acid use (P = .02). After adjusting for confounders, no predictors were associated with composite neonatal morbidity. TBA 40-99.9 μmol/L and TBA ≥100 μmol/L were associated with increased risk of meconium-stained amniotic fluid (adjusted odds ratio, 3.55; 95% confidence interval, 1.45-8.68 and adjusted odds ratio, 4.55; 95% confidence interval, 1.47-14.08, respectively). CONCLUSION: In women with ICP, TBA level ≥100 μmol/L was associated with increased risk of stillbirth. TBA ≥40 μmol/L was associated with increased risk of meconium-stained amniotic fluid.
OBJECTIVE: We sought to determine predictors of adverse neonatal outcomes in women with intrahepatic cholestasis of pregnancy (ICP). STUDY DESIGN: This study was a multicenter retrospective cohort study of all women diagnosed with ICP across 5 hospital facilities from January 2009 through December 2014. Obstetric and neonatal complications were evaluated according to total bile acid (TBA) level. Multivariable logistic regression models were developed to evaluate predictors of composite neonatal outcome (neonatal intensive care unit admission, hypoglycemia, hyperbilirubinemia, respiratory distress syndrome, transient tachypnea of the newborn, mechanical ventilation use, oxygen by nasal cannula, pneumonia, and stillbirth). Predictors including TBA level, hepatic transaminase level, gestational age at diagnosis, underlying liver disease, and use of ursodeoxycholic acid were evaluated. RESULTS: Of 233 women with ICP, 152 women had TBA levels 10-39.9 μmol/L, 55 had TBA 40-99.9 μmol/L, and 26 had TBA ≥100 μmol/L. There was no difference in maternal age, ethnicity, or prepregnancy body mass index according to TBA level. Increasing TBA level was associated with higher hepatic transaminase and total bilirubin level (P < .05). TBA levels ≥100 μmol/L were associated with increased risk of stillbirth (P < .01). Increasing TBA level was also associated with earlier gestational age at diagnosis (P < .01) and ursodeoxycholic acid use (P = .02). After adjusting for confounders, no predictors were associated with composite neonatal morbidity. TBA 40-99.9 μmol/L and TBA ≥100 μmol/L were associated with increased risk of meconium-stained amniotic fluid (adjusted odds ratio, 3.55; 95% confidence interval, 1.45-8.68 and adjusted odds ratio, 4.55; 95% confidence interval, 1.47-14.08, respectively). CONCLUSION: In women with ICP, TBA level ≥100 μmol/L was associated with increased risk of stillbirth. TBA ≥40 μmol/L was associated with increased risk of meconium-stained amniotic fluid.
Authors: Jamie O Lo; Brian L Shaffer; Allison J Allen; Sarah E Little; Yvonne W Cheng; Aaron B Caughey Journal: J Matern Fetal Neonatal Med Date: 2014-11-28
Authors: A J Rioseco; M B Ivankovic; A Manzur; F Hamed; S R Kato; J T Parer; A M Germain Journal: Am J Obstet Gynecol Date: 1994-03 Impact factor: 8.661
Authors: Sven Kehl; Irene Hösli; Ulrich Pecks; Philipp Reif; Ralf L Schild; Markus Schmidt; Dagmar Schmitz; Christiane Schwarz; Daniel Surbek; Michael Abou-Dakn Journal: Geburtshilfe Frauenheilkd Date: 2021-08-09 Impact factor: 2.754
Authors: Maria C Estiú; Maria A Frailuna; Carla Otero; Marcela Dericco; Catherine Williamson; Jose J G Marin; Rocio I R Macias Journal: PLoS One Date: 2017-04-24 Impact factor: 3.240